AR1001

DRUG3 trials

Sponsors

Aribio Co. Ltd., AriBio Co., Ltd.

Conditions

Alzheimer DiseaseAlzheimer’s DiseaseMild to Moderate Alzheimer's Disease

Phase 2

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

CompletedNCT03625622

AriBio Co., Ltd.Mild to Moderate Alzheimer's Disease

Start: 2019-04-01End: 2021-06-28Updated: 2021-07-21

Phase 3

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

Active, not recruitingNCT05531526

AriBio Co., Ltd.Alzheimer Disease

Start: 2022-12-23End: 2027-12-31Updated: 2025-10-02

A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease.

Active, not recruitingCTIS2023-508306-15-00

Aribio Co. Ltd.Alzheimer’s Disease

Start: 2024-06-26Target: 456Updated: 2026-01-22

Related Papers

Multiple Beneficial Effects of AR1001 on Aβ‐Induced Changes in Human Minibrain

Alzheimer s & Dementia2025-12-01

A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease

The Journal of Prevention of Alzheimer s Disease2025-09-052 citations

Target Engagement and Therapeutic Effects of AR1001, a Phosphodiesterase‐5 Inhibitor, in Alzheimer’s Disease Models

Alzheimer s & Dementia2024-12-01

Protective Effects of AR1001 in Alzheimer’s Disease Models: Polypharmacological Mechanisms

Alzheimer s & Dementia2023-12-012 citations